Class Action Lawsuit Filed Against EyePoint, Inc. Over DURAVYU Clinical Trial Disclosures
EyePoint, Inc. (NASDAQ: EYPT) is facing a class action lawsuit following allegations that the company misled investors regarding the efficacy and commercial viability of its therapeutic, DURAVYU, intended for treating wet age-related macular degeneration (wet AMD). The complaint alleges that while the company touted 'best-in-class' efficacy during Phase 3 LUGANO and LUCIA trials, it failed to disclose that the drug was less effective than previously suggested. The stock suffered massive declines following disappointing clinical results. On August 17, 2026, shares fell approximately 67% after the company reported failing to meet a primary endpoint in the LUGANO trial. A subsequent drop of over 85% occurred on October 19, 2026, following poor LUCIA trial results and the announcement that EyePoint would terminate its wet AMD clinical program and reduce its workforce by 53%.
Coverage
- Class Action Lawsuit Filed Against EyePoint, Inc. Over DURAVYU Clinical Trial Disclosures
- Chemomab Therapeutics Q3 results
- Berger Montague Announces Class Action Lawsuit Against Tenax Therapeutics Following Phase 3 Trial Failure
- Milestone Pharmaceuticals Inc. - 8-K Filing
- VISTA GOLD CORP - 8-K Filing
- Stark Novus Financial Inc. - 8-K Filing